Press
September 13, 2021

LARVOL Launches the First Cancer-Focused Social Listening Platform for Pharma and Oncology

Press
April 13, 2021

LARVOL Launches the First Cancer-Focused Social Listening Platform for Pharma and Oncology

Author

LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced the launch of VIEW, the first curated social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and Digital Opinion Leaders (DOLs). Access to this curated information will enable pharma marketers, competitive intelligence, and medical affairs teams to make informed, up-to-the-minute decisions influencing their oncology drug positioning.

San Francisco, CA (April 13, 2021)BUSINESS WIRELARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced the launch of VIEW, the first curated social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and Digital Opinion Leaders (DOLs). Access to this curated information will enable pharma marketers, competitive intelligence, and medical affairs teams to make informed, up-to-the-minute decisions influencing their oncology drug positioning.

VIEW represents a new age in the relationship between pharmaceutical teams and the physicians they rely on for insights into the clinical impact of their products. The online platform presents trending cancer news curated by experts, combined with sentiment analysis, influencer ranking, and polling data from Twitter’s top oncologists. This focused analysis enables drug developers and marketers to get an accurate read on the competitive landscape and to effectively identify and engage with DOLs in oncology.

“Top oncologists are now using Twitter to share their opinions on trials, treatments, and the experience of their patients in real time,” says LARVOL Founder and CEO Bruno Larvol. “Pharma teams understand the importance of these DOLs as experts in their field and influencers of their peers, but the cancer conversation is moving too quickly for anyone to interpret on their own. VIEW gives them an intuitive platform to tap into the immediate conversations, identify experts, measure sentiment, and more.”

LARVOL’s expert analysts focus on the real-time activity of more than 1,500 verified oncologists on Twitter. Analysts manually review and code each tweet to express the doctor’s sentiment to trending news as positive or negative. The result is a meaningful and authentic picture for pharma teams of the oncology community’s response to breaking cancer news.

“What makes VIEW unique is the added layer of sentiment analysis,” says LARVOL Head of Operations, Sabrina Bellisario. “Text-based listening programs can’t interpret the meaning behind a tweet, but our experts can, and they do it almost as fast as the oncologists can tweet.”

VIEW is live now and will be officially launched at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference on April 27. As the latest oncology-focused solution from LARVOL, this tool represents the company's commitment to being a part of the future of discovery and innovation in cancer treatment. For more information visit LARVOL.com.

 

About LARVOL:

LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.